July 28, 2016
Mayo Clinic Studying Genomics of Antiplatelet Heart Medication
By Sharon Rosen
Angioplasty offers lifesaving treatment without open heart surgery. But, it comes with risks. Researchers at the Center for Individualized Medicine are trying to determine if your individual genetic blue print can pinpoint drugs that reduce the risk of dangerous side effects. The Tailored Antiplatelet Therapy to Lessen Outcomes After Percutaneous Coronary Intervention (TAILOR-PCI) Study examines […]
Tags: #Antiplatlet Heart Medication, #Ticagrelor, angioplasty, Biomedical research, clopidogrel, Dr. Chet Rihal, Dr. Naveen Pereira, medical research, pharmacogenomics
February 4, 2014
Studying the Genomics of Antiplatelet Heart Medication
By Center for Individualized Medicine
Which antiplatelet medication is best after a coronary stent? The answer may lie in your genes, but heart experts differ with the Food and Drug Administration on when to do genotype testing on angioplasty patients and whether genetic testing will keep heart patients out of the emergency rooms. Around 600,000 angioplasties are performed every year in the United […]
Tags: angioplasties, angioplasty, antiplatelet medication, Brilinta, Center for Individualized Medicne, DNA Sequencing, individualized medicine, Personal Care, Personal Medicine, pharmacogenomics, Plavix, TAILOR
August 20, 2013
Genomics May Settle Debate on Best Antiplatelet Medication After Stenting
By AJ Montpetit
600,000 angioplasties are performed every year in the United States, which has raised the question of which antiplatelet medication is best after a coronary stent. Looking to individual’s genome is where the Center for Individualized Medicine is studying, with their newly launched TAILOR-PCI study. This study examines the CYP2C19 genotype of a patient to determine […]
Tags: angioplasty, antiplatelet, antiplatelet medication, center for individualized medicine, individualized medicine, mayo clinic, personalized medicine, pharmacogenomics